Skip to main content

Table 6 Efficacy of first-line treatment and second-line treatment in lenvatinib monotreatment group

From: Efficacy and safety of lenvatinib monotreatment and lenvatinib-based combination therapy for patients with unresectable hepatocellular carcinoma: a retrospective, real-world study in China

LEN (n = 39)

First-line treatment (n = 27)

Second-line treatment (n = 12)

CR

0

0

PR

5

1

SD

12

9

PD

10

2

ORR

19%

8%

DCR

63%

83%

  1. LEN, lenvatinib; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; ORR, objective response rate; DCR, disease control rate